Home » Newsletters » BioWorld

BioWorld

Dec. 9, 1993

View Archived Issues

SCICLONE FILES FOR FOLLOW-ON OFFERING

ATHENA UNDERWRITERS EXERCISE OPTION

LIFECELL TO TEAM UP WITH MEDTRONIC

ONCOGENE SCIENCE RECEIVES TWO PATENTS

ONCOSCINT PROSTATE EVALUATES PROSTATE CANCER

COCENSYS FILES INDS ON ANTI-EPILEPSY DRUG

IMMUNOGEN REPORTS ONCOLYSIN B PHASE II DATA

CELL THERAPEUTICS REPORTS ON IL-2 SIGNALING PATHWAY

NOVOPHARM AND DEPRENYL RESEARCH MARKETING ALLIANCE

PIG SEQUENCE DESIGNED TO FOIL FACTOR VIII INHIBITION

CISTRON SUES IMMUNEX OVER IL-1B PATENT

RHONE-POULENC GETS RIGHTS TO MARKET ENZON'S ONCASPAR

$5 BILLION NIH RESEARCH FUND PROPOSED

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....